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Clinical Laboratory Assessment of Mycoplasma genitalium
Transcription-Mediated Amplification Using Primary Female
Urogenital Specimens
Erik Munson,a,b Holly Bykowski,a Kimber L. Munson,a Maureen Napierala,a Pamela J. Reiss,a Ronald F. Schell,c,d,e Jeanne E. Hryciuka

Following analysis of primary cervix, vagina, and first-void female urine specimens for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis via commercial transcription-mediated amplification (TMA), residual material was subjected
to Mycoplasma genitalium research-use-only TMA. Representation within a 2,478-specimen retrospective study set was established by comparison to a 6-month audit of clinical C. trachomatis TMA (12,999 specimens) on the basis of the C. trachomatis
detection rate, specimen source distribution, clinic location, and age. M. genitalium was detected in 282 (11.4%) patients. This
rate was higher than those seen with T. vaginalis (9.0%; P ⴝ 0.005), C. trachomatis (6.2%), and N. gonorrhoeae (1.4%). Positive
M. genitalium results were confirmed by repeat testing or alternative-target TMA at a rate of 98.7%. The mean age of the M.
genitalium-infected females (24.7 years) was lower than that of the T. vaginalis-infected females (mean, 30.1 years; P < 0.0001)
and higher than that of the C. trachomatis-infected females (mean, 23.8 years; P ⴝ 0.003). Of 566 patient encounters positive for
at least one sexually transmitted infection (STI), 35.9% exhibited sole detection of M. genitalium (P < 0.0004 versus sole detection of other STI agents) and 26.1% were solely positive for T. vaginalis (P < 0.0002 versus C. trachomatis). The M. genitalium and T. vaginalis detection rates among 755 patients at urban emergency departments were 14.6% and 13.0%, respectively
(P ⴝ 0.37). A 10.0% M. genitalium detection rate from other facilities exceeded that of T. vaginalis (7.2%; P ⴝ 0.004). Incorporation of M. genitalium TMA into comprehensive testing programs would detect M. genitalium in a significant proportion of females, particularly those in outpatient obstetrics and gynecology (OB/GYN) settings.

T

he sexually transmitted infection (STI) agent Mycoplasma
genitalium has historically had a role of pathogenicity in male
nongonococcal urethritis (1). Recent evidence has implicated the
bacterium in clinically significant disease in females (2, 3). Additional studies suggest that M. genitalium infection promotes HIV
acquisition (4–6) and virus shedding (7, 8). Moreover, in a recent
meta-analysis, Lis et al. (9) reported significant associations between M. genitalium infection and cervicitis, pelvic inflammatory
disease, preterm birth, and spontaneous abortion.
Until recently, a lack of reliable testing options has curtailed
laboratory diagnosis of M. genitalium infection. Culture and serologic modalities have been limited by sensitivity and/or cross-reactivity with other mycoplasmas (1) and are becoming supplanted
by molecular diagnostics, largely on a research basis. PCR-based
assays have correlated M. genitalium DNA burden with clinical
condition (10, 11) and treatment efficacy (12) in males. Quantitative molecular analysis has sought to study progression of genital disease in females (13). In the realm of laboratory diagnosis,
initial studies of target capture-based transcription-mediated
amplification (TMA) in females reported 87.8% (14) and
96.9% (15) sensitivity values from vaginal specimens. PCR sensitivity values from the same cohorts were 92.9% and 93.8%,
respectively.
We recently demonstrated the utility of TMA-based M. genitalium detection in male specimens originating from both STI and
community outpatient clinics (16). In contrast, previous studies
of M. genitalium TMA in females have largely focused on high-risk
demographics (14, 15, 17–19). Assessment of M. genitalium detection rates in a communitywide setting would be beneficial. We
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now provide findings of the importance of TMA-based M. genitalium evaluation of females in a metropolitan health care system.
(Results of this work were previously presented, in part, at the
115th General Meeting of the American Society for Microbiology,
New Orleans, LA, 30 May to 2 June 2015.)
MATERIALS AND METHODS
Setting. In addition to seven acute care facilities, Wheaton Franciscan
Laboratory serves an approximately 125-clinic metropolitan outpatient
physician group in a three-county region of southeastern Wisconsin. A
portion of this service area extends beyond the Milwaukee-WaukeshaWest Allis metropolitan statistical area (MSA). Analyses of data from U.S.
MSAs document a long-standing trend of high STI prevalence in the Milwaukee-Waukesha-West Allis MSA. Aggregation of these data revealed an
average chlamydia rate of 678.0 per 100,000 population over a 10-year
interval (20). This value averaged the second highest in the United States
and represented a 77.3% increase over the average national cumulative
MSA rate of 382.3 per 100,000 population. The same MSA generated an
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TABLE 1 Distribution of specimen source submissions and C. trachomatis detection rates during a 6-month audit of routine C. trachomatis
screening, with comparison to representative distributions of specimens collected for retrospective M. genitalium TMA analysis
% source distribution within specimens analyzed
in:

% C. trachomatis detection from specimens
analyzed in:

C. trachomatis routine
screening

M. genitalium TMA
assessment

P value

C. trachomatis routine
screening

M. genitalium TMA
assessment

P value

Cervix
Urine
Vagina

77.7
17.5
4.8

76.5
17.9
5.6

0.20
0.65
0.10

6.2
6.3
6.9

6.2
6.1
6.5

0.99
0.85
0.87

6.3

6.2

0.91

Total

average annual rank of 2.56 for gonorrhea rate among United States MSAs
(264.0 per 100,000 population; 112.6% higher than the national MSA rate
of 124.2 per 100,000 population).
Specimen submission for routine screening. Approximately 2-ml
aliquots of first-void female urine were added to Aptima urine specimen
transport tubes per the Aptima Combo 2 Assay (Hologic, Incorporated,
San Diego, CA) package insert protocol following specimen procurement
(21). Aliquots were stored at 2 to 30°C and tested within 30 days of primary collection. Primary genital swab specimens were obtained using an
Aptima unisex swab specimen collection kit (21), stored at 2 to 30°C, and
tested within 30 days of collection.
The Aptima Combo 2 Assay was utilized for the detection of N. gonorrhoeae-specific 16S rRNA and Chlamydia trachomatis-specific 23S
rRNA (22) from all urine aliquots. The samples were additionally subjected to Aptima Trichomonas vaginalis (Hologic) testing for detection of
organism-specific 18S rRNA (23).
Retrospective specimen collection for M. genitalium TMA analysis.
A 6-month laboratory information system-based audit of female STI ordering practices was conducted for the purpose of assembling a representative study set for M. genitalium TMA. Assessed parameters included
specimen source (urine, cervical specimen, or vaginal specimen), C. trachomatis detection rate, geographic location, and patient age. This study
was governed by the Wheaton Franciscan Healthcare Institutional Review
Board.
Molecular detection of M. genitalium. Residual clinical material was
subjected to a research-use-only TMA-based assay for detection of M.
genitalium-specific 16S rRNA (referred to as M. genitalium TMA; Hologic). Reagents were prepared by using Aptima general-purpose reagents
spiked with M. genitalium-specific oligonucleotides. A 50-l aliquot of
target capture oligonucleotide was spiked into Aptima target capture reagent; 50-l aliquots of T7 and non-T7 oligonucleotides were spiked into
reconstituted Aptima reconstitution reagent; and a 50-l aliquot of acridinium ester-labeled hybridization oligonucleotide was spiked into Aptima hybridization buffer. All assays were performed on an automated
TIGRIS DTS platform (Hologic).
Interpretation of results. M. genitalium TMA relative-light-unit values of ⱖ50,000 derived from urogenital specimen testing were interpreted
as representing positive results (14, 17). A subset of positive results, as
each residual specimen allowed, was confirmed by repeat testing. An additional subset of positive specimens was forwarded for a TMA-based
alternative-target confirmatory assay (Hologic).
Statistical analysis. The STI phenotype was defined as a M. genitalium, C. trachomatis, N. gonorrhoeae, and T. vaginalis distribution within a
given health care encounter that yielded detection of at least one STI
agent. The significance test of proportions determined if differences in
either the rates of positive screening results or the STI phenotypes were
significant. The t test for independent samples determined if differences in
mean patient age associated with positive results were significant in the
comparisons between STI etiologies. The alpha level was set at 0.05 before
the investigations commenced, and all P values are two tailed.
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RESULTS

Collection of specimens for M. genitalium TMA assessment.
Retrospectively collected specimens (n ⫽ 2,478) were compared
to data gathered from a 6-month audit of routine screening practices for C. trachomatis. Proportional specimen source distributions did not differ between routine C. trachomatis screening
practices and specimens gathered for M. genitalium TMA (P ⱖ
0.10; Table 1). In addition, C. trachomatis detection rates showed
no difference from those seen in the collection for M. genitalium
TMA (P ⫽ 0.91). Detection rates stratified by specimen source
were also similar (P ⱖ 0.85; Table 1). Among the urogenital specimens submitted for routine C. trachomatis screening, 18.6% and
48.0% were derived from females aged ⱕ20 and 21 to 30 years,
respectively. Analogous proportions collected for M. genitalium
TMA were 19.0% and 47.0% (P ⫽ 0.60 and 0.38, respectively; data
not illustrated). Comparative data for successive age in decades
exhibited no differences (P ⱖ 0.07).
Twenty health care locations accounted for 89.2% of all routine C. trachomatis submissions (Table 2). No differences in proportional specimen distributions between routine laboratory C.
trachomatis screening and the M. genitalium TMA collection (P ⫽
0.11) or stratified by individual health care location (P ⱖ 0.28)
were noted. These entities were also the basis for arbitrary categorization of health care locations as outpatient obstetrics and
gynecology (OB/GYN), inpatient OB/GYN, suburban family
care, urban family care, and emergency room (ER)/urgent care.
Moreover, 242 (9.8%) specimens in the M. genitalium TMA
collection originated from 34 additional health care locations (Table 2).
Detection of M. genitalium RNA. The overall detection rate of
M. genitalium (11.4%) exceeded those of the other STI agents (P ⱕ
0.005). T. vaginalis also demonstrated increased detection (9.0%
rate) versus C. trachomatis and N. gonorrhoeae (P ⱕ 0.0003). Detection rates for C. trachomatis and N. gonorrhoeae were 6.2% and
1.4%, respectively. A total of 208 specimens with detectable M.
genitalium contained enough residual material to allow for repeat
analysis; 207 (99.5%) yielded a positive result. In addition, a subset
of 242 specimens was subjected to alternative-target TMA analysis
(Table 3). A 98.8% concordance of results was observed.
Female urogenital specimens with detectable M. genitalium
RNA. The rates of detection of M. genitalium from 1,896 cervical,
444 urine, and 138 vaginal specimens were 11.5%, 10.1%, and
13.8%, respectively (P ⱖ 0.23; Fig. 1). In similar fashion, the C.
trachomatis and N. gonorrhoeae detection rates, stratified by specimen source, revealed no differences (P ⱖ 0.85 and 0.18, respec-
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Specimen
source

Munson et al.

TABLE 2 Distribution of specimen submissions among the 20 most
frequently visited health care locations during a 6-month audit of
routine C. trachomatis screening and comparison to representative
distributions of specimens collected for retrospective M. genitalium
TMA analysis

Health care location

a
b

% total specimen
collections for M.
genitalium TMA
assessmentb

P value

16.69
9.12
4.14
3.21
3.02
1.96
1.54
1.52
1.46
3.62
1.58
5.36
3.21
2.93
11.95
4.85
5.12
4.06
2.66
1.15
89.2
10.8

16.38
9.60
4.08
3.39
3.39
1.86
1.45
1.49
1.69
3.55
1.53
5.37
3.55
2.70
12.47
4.96
5.00
3.79
2.54
1.41
90.2
9.8

0.71
0.44
0.89
0.64
0.33
0.73
0.75
0.91
0.38
0.86
0.87
0.99
0.38
0.54
0.46
0.80
0.82
0.53
0.73
0.28
0.11
0.11

Positive
Negative

tively). The T. vaginalis detection rate from urine (11.3%) exceeded the rate from cervical specimens (8.2%; P ⬍ 0.04) and
was similar to the detection rate (11.6%) from vaginal specimens (P ⫽ 0.91).
The detection rate of M. genitalium in females aged ⱕ20 years
was 16.8%. This rate decreased for each successive age decade (Fig.
2), leading to a 4.6% value in a subset of 22 females aged ⬎60
years. M. genitalium was detected in females 14 years to 65 years of
age, with a mean age of 24.7 years (data not illustrated). This mean
was similar to the mean age of N. gonorrhoeae detection (23.5
years; P ⫽ 0.30) but different from those for C. trachomatis detection (22.8 years; P ⫽ 0.003) and T. vaginalis detection (30.1 years;
P ⬍ 0.0001).
M. genitalium detection delineated by health care setting.
Other than a 9.0% rate of C. trachomatis detection from the ER/
urgent care setting, C. trachomatis and N. gonorrhoeae detection
rates did not exceed 5.4% for a given health care setting (data not
illustrated). Two health care locations, ER/urgent care and outpatient OB/GYN, accounted for 72.1% of specimens analyzed by M.
genitalium TMA. Specimens from outpatient OB/GYN were more
likely to contain detectable M. genitalium than T. vaginalis (P ⫽
0.001; Table 4). In contrast, specimens from ER/urgent care had
similarly high rates of M. genitalium and T. vaginalis detection
(14.6% and 13.0%, respectively; P ⫽ 0.37).
Codetection of other STI agents with M. genitalium. M. genitalium was a component of 49.8% of the female STI phenotypes

jcm.asm.org

No. of M. genitalium TMA results
Positive

Negative

27
2

1
212

and the sole component of 35.9% of the phenotypes in this study
(Table 5). Sole detection of T. vaginalis was observed with 26.1%
of the phenotypes; T. vaginalis was a constituent of 39.2% of the
STI phenotypes (P ⱕ 0.0004 compared to M. genitalium). These
values were greater than the analogous data for C. trachomatis and
N. gonorrhoeae.
In general, equal abundances of M. genitalium- and T. vaginalis-based STI phenotypes existed among the inpatient OB/GYN,
family care, and ER/urgent care settings (P ⱖ 0.26; Table 5). However, 41.3% of the outpatient OB/GYN phenotypes consisted of
sole M. genitalium detection, while sole detection of T. vaginalis
comprised 21.8% of the phenotypes (P ⬍ 0.0002).
Of the 282 specimens with detectable M. genitalium, only
28.0% revealed detection of an additional STI agent (data not
illustrated). Between 28.6% and 36.6% of inpatient OB/GYN,
family care, and ER/urgent care specimens with detectable M.
genitalium involved codetection with another STI agent. In contrast, only 19.8% of the outpatient OB/GYN specimens testing
positive for M. genitalium exhibited an additional STI agent.
DISCUSSION

Total submissions, 12,999.
Total collections, 2,478.

434

Alternative-target TMA
result

Evidence for the clinical significance of M. genitalium in female
reproductive tract disease is increasing. Lis et al. (9) demonstrated
a significant association of M. genitalium incidence and increased
risk of cervicitis with a pooled odds ratio (OR) of 1.65. A pooled
OR of 2.53 (adjusted for coinfection) was calculated for an association with pelvic inflammatory disease. When studies utilizing
serodiagnosis were excluded, the OR increased to 2.73. Additional
meta-analyses associated M. genitalium infection with increased
risk of preterm birth (pooled OR of 2.33, accounting for coinfection) and spontaneous abortion (pooled OR of 1.82). These data
point out a clinical need for effective laboratory diagnostics specific to this STI agent.
Our data show elevated rates of M. genitalium detection in
females, with significantly greater rates than those for Trichomonas vaginalis—a pathogen previously demonstrated to be present
in abundance in the high-prevalence Milwaukee STI community
(24, 25). Of 282 detections of M. genitalium, 237 were subjected to
confirmation by repeat testing or alternative-target TMA; 98.7%
of such tests yielded a positive result. Previous literature has espoused the value of repeat testing in the confirmation of positive
TMA results (26). Furthermore, in the course of determining the
specificity of M. genitalium TMA, 213 TMA-negative specimens
were subjected to alternative-target TMA. Only one specimen
(0.5%) yielded a positive result by alternative-target TMA. This
rate of discordant results was less than the 1.6% to 4.6% values
reported for T. vaginalis alternative-target testing (24, 27, 28). The
parasitic species Trichomonas tenax has substantial genetic homology with T. vaginalis (29), which hypothetically could contribute to decreased specificity of T. vaginalis alternative-target TMA,
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Outpatient OB/GYN 1
Outpatient OB/GYN 2
Outpatient OB/GYN 3
Outpatient OB/GYN 4
Outpatient OB/GYN 5
Outpatient OB/GYN 6
Outpatient OB/GYN 7
Outpatient OB/GYN 8
Inpatient OB/GYN
Suburban family care 1
Suburban family care 2
Urban family care 1
Urban family care 2
Urban family care 3
ER/urgent care 1
ER/urgent care 2
ER/urgent care 3
ER/urgent care 4
ER/urgent care 5
ER/urgent care 6
Top 20 locations
34 other health care
locations

% total specimen
submissions for
C. trachomatis
screeninga

TABLE 3 Tandem performance of M. genitalium TMA and alternativetarget TMA assays on a subset of 242 primary female urogenital
specimens

Mycoplasma genitalium Detection in Females

particularly in cases of pharyngeal T. vaginalis carriage (28). The
high specificity for M. genitalium alternative-target TMA implies
lack of cross-reactivity with other mycoplasmas and clearly verifies the increased M. genitalium detection in this population.
Previous studies of M. genitalium TMA have focused largely on
high-risk demographics. Huppert et al. (17) reported a 22.4% detection rate from 331 female attendees of an adolescent health
center/emergency department. Furthermore, Gaydos et al. (18)
documented an approximate 19% detection rate among female
STI clinic patients. A major strength of our large-scale study is the
extrapolation of M. genitalium TMA to primary clinical practice in
a broad geographic area. Data from Tables 1 and 2 confirm the
representative nature of the study set. Past reports from our laboratory have summarized diagnostic assay performance within
high-prevalence STI cohorts (16, 20). Subsequent to these reports,
our laboratory has extended its testing scope to locales outside the
Milwaukee-Waukesha-West Allis MSA. While this has resulted in
decreases of STI etiology detection by the laboratory (e.g., the C.

trachomatis detection rate at [non-MSA] ER/urgent care 3 was
8.9%, while the analogous detection rate at [MSA] ER/urgent care
1 was 13.3%; data not illustrated), it has also provided a diverse
population basis for practical assessment of commercial M. genitalium TMA.
Past surveillance efforts in general European and U.S. female
populations using molecular diagnostics (30, 31) have reported
M. genitalium detection rates of 1.0% to 2.3%. A meta-analysis
published by McGowin and Anderson-Smits (32) calculated a detection rate of 2.0% from low-risk female populations. In a South
American OB/GYN cohort of 1,338 women, Hitti et al. (33) documented a 3.1% cervical M. genitalium detection rate by TMA.
This report is interesting for a number of reasons. First, it documents M. genitalium detection in an OB/GYN population and
associates its presence with preterm birth and younger maternal
age. It also reveals a strong association with C. trachomatis detection and a marginal association with T. vaginalis detection. It
should be noted that those authors utilized culture for laboratory

FIG 2 M. genitalium (solid bars), C. trachomatis (horizontally hatched bars), N. gonorrhoeae (gray bars), and T. vaginalis (diagonally hatched bars) detection
rates, delineated by age, from 2,478 female urogenital specimens.
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FIG 1 Cervical, first-void urine, and vaginal specimen detection rates for M. genitalium (solid bars), C. trachomatis (horizontally hatched bars), N. gonorrhoeae
(gray bars), and T. vaginalis (diagonally hatched bars) from 2,478 female patients.

Munson et al.

TABLE 4 M. genitalium and T. vaginalis detection rates for females
seeking health care in ER/urgent care and non-ER/urgent care settings
No. (%) of specimens with
detection of:
Health care setting

n

M. genitalium

T. vaginalis

P value

Outpatient OB/GYN
Inpatient OB/GYN
Suburban family care
Urban family care
ER/urgent care

1,032
46
261
384
755

106 (10.3)
7 (15.2)
18 (6.9)
41 (10.7)
110 (14.6)

66 (6.4)
5 (10.9)
14 (5.4)
39 (10.2)
98 (13.0)

0.001
0.54
0.47
0.81
0.37

TABLE 5 Sexually transmitted infection phenotypes determined by TMA-based assays specific for M. genitalium, C. trachomatis, N. gonorrhoeae,
and T. vaginalis, delineated by category of health care setting
STI phenotypea,b

No. (%) of specimens with indicated phenotype(s)b

M. genitalium

C. trachomatis

N. gonorrhoeae

T. vaginalis

Outpatient
OB/GYN

Inpatient
OB/GYN

Suburban
family care

Urban
family care

ER/urgent
care

Totalc

⫹
⫹
⫹
⫺
⫺
⫺
⫺
⫺

⫺
⫹
⫺
⫹
⫹
⫹
⫺
⫺

⫺
⫺
⫺
⫺
⫹
⫺
⫹
⫺

⫺
⫺
⫹
⫺
⫺
⫹
⫺
⫹

85 (41.3)
3 (1.5)
14 (6.8)
43 (20.9)
1 (0.5)
7 (3.4)
4 (1.9)
45 (21.8)

5 (41.7)
2 (16.7)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
5 (41.7)

12 (29.3)
3 (7.3)
1 (2.4)
8 (19.5)
1 (2.4)
0 (0.0)
1 (2.4)
13 (31.7)

26 (33.8)
2 (2.6)
11 (14.3)
9 (11.7)
0 (0.0)
2 (2.6)
0 (0.0)
25 (32.5)

75 (32.6)
14 (6.1)
14 (6.1)
30 (13.0)
4 (1.7)
14 (6.1)
8 (3.5)
60 (26.1)

203 (35.9)
24 (4.2)
40 (7.1)
90 (15.9)
6 (1.1)
23 (4.1)
13 (2.3)
148 (26.1)

⫹, positive nucleic acid amplification test result; ⫺, negative nucleic acid amplification test result; STI, sexually transmitted infection.
Phenotypes that were observed in ⱖ1.5% of patients from at least two health care settings are included. No significant difference was noted within the excluded comparisons.
c
Phenotypes that were observed in ⬍1.0% of encounters are not included in this category. M. genitalium was a constituent of 49.8% of all phenotypes, C. trachomatis of 27.2%, N.
gonorrhoeae of 6.0%, and T. vaginalis of 39.2%.
a
b
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diagnosis of trichomoniasis, a modality shown to be far less sensitive than molecular diagnostics (34). Our outpatient OB/GYN
population was characterized by an increased rate of M. genitalium in general and by a significantly increased rate of M. genitalium detection in comparison to T. vaginalis detection (P ⫽ 0.001;
Table 4).
STI phenotyping essentially predicts the likelihood of a given
etiology for STI diagnosis during a health care encounter. In contrast to past reports showing a strong association between M. genitalium detection and the concomitant presence of C. trachomatis
(17, 33), only 4.2% of total STI phenotypes in our study involved
codetection of M. genitalium and C. trachomatis (Table 5). Among
the STI phenotypes, 7.1% consisted of M. genitalium and T. vaginalis codetection. Moreover, while M. genitalium was a constituent of nearly half of the STI phenotypes, 39.2% and 27.2% of all
phenotypes had some component of T. vaginalis and C. trachomatis, respectively. Detection rate and STI phenotype data reveal significant differences with respect to M. genitalium and T. vaginalis
in the outpatient OB/GYN setting. These clinics were more likely
to produce a significant increase in M. genitalium detection (Table
4) as well as STI phenotypes specific to the organism (Table 5).
The other four arbitrary health care classifications did not experience this phenomenon. Napierala et al. (16) previously described
a M. genitalium/T. vaginalis dichotomy within a 2,750-male cohort in which the STI phenotypes of STI clinic attendees and patients seeking outpatient clinic care consisted predominately of M.
genitalium and T. vaginalis, respectively. The differential distribution of these two STI agents, which apparently may exist to a
degree in both genders, warrants further investigation.

With respect to an optimal specimen source for TMA-based
detection of M. genitalium on a single-specimen basis, Wroblewski et al. (14) discussed the relative sensitivities of vaginal and
cervical specimens, which were 84% and 60%, respectively. The
relative sensitivity of first-void urine specimens was 58% and was
thought to be the result of increased susceptibility of a cell walldevoid microbe to lysis in urine. Using an infected-patient standard, Mobley et al. (19) reported TMA-based M. genitalium sensitivities of 72.6% and 58.9% from vaginal and cervical specimens,
respectively. Our data reveal equivalent M. genitalium detection
rates from cervical specimens (11.5%), vaginal specimens
(13.8%), and first-void urine (10.1%; P ⱖ 0.23). However, our
data are limited by the fact that not all three specimen sources were
submitted from a given patient during routine clinical practice.
Therefore, comparison of performance characteristics by specimen source could not be accomplished in this retrospective assessment. Of further interest, previous studies in our female patient
population demonstrated increased T. vaginalis detection from
first-void urine specimens (25, 35). We also show increased T.
vaginalis detection from first-void urine compared to cervical
specimens (P ⫽ 0.04; Fig. 1). These data trended higher than the
combined cervical specimen/vaginal specimen data (P ⫽ 0.06).
Some concern lies in how the increased utility of the first-void
urine specimen for T. vaginalis could coexist with the aforementioned M. genitalium data in the context of (single) specimen
source recommendations for a four-agent STI screen. Additional
large-scale communitywide studies may be necessary to determine the true utility of urine for M. genitalium TMA, particularly
when such specimens would be assayed for the organism in routine fashion without prolonged specimen storage.
In summary, increased detection rates of M. genitalium in a
communitywide setting over those of other STI agents, including
T. vaginalis, suggest that M. genitalium TMA can provide a benefit
to multiple demographics and multiple clinical practice specialties. In addition, the setting of the outpatient OB/GYN is itself an
important area for M. genitalium screening. M. genitalium TMA
has recently become commercially available in an analyte-specific
reagent (ASR) format. Prior to FDA clearance in 2011, T. vaginalis
TMA was also commercially available as an ASR. Napierala et al.
(35) demonstrated progressively increased utilization of that assay
over a 3-year interval. Should an analogous pattern be observed
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with M. genitalium ASR, potential benefits of a more-comprehensive STI screen may be realized in the realm of laboratory diagnosis and public health.
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